Vertex Pharma (VRTX): Recent Weakness Skews Risk/Reward To Favorable - Jefferies

October 18, 2016 9:23 AM EDT
Get Alerts VRTX Hot Sheet
Price: $75.58 +0.11%

Rating Summary:
    25 Buy, 16 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 27 | Down: 20 | New: 14
Trade VRTX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) on the belief that the recent Orkambi launch slowdown and concerns over a no next-gen corrector news are overdone.

The analyst believes that the share price does not fully reflect 1) the potential for cash flow expansion through 3x-combos which should ultimately work, 2) a leadership position and barrier to entry for future competitors, and 3) leverage even if there are stumbles.

The analyst perceives the upside/downside scenarios as favorably skewed at (~50%/13%), creating a highly attractive entry point.

price target of $105.00

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here

Shares of Vertex closed at $80.50 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment